Epidermal growth factor receptor mutation status and Rad51 determine the response of glioblastoma to multimodality therapy with cetuximab, temozolomide, and radiation.

Published in:

Frontiers in Oncology, 2013, v. 3, p. 1, doi. 10.3389/fonc.2013.00013

By:

• Wachsberger, Phyllis Rachelle;
• Lawrence, Richard Yaacov;
• Yi Liu;
• Rice, Barbara;
• Daskalakis, Constantine;
• Dicker, Adam P.;
• Zhenkun Lou;
• Prise, Kevin

Publication type:

Article